MA27724A1 - Utilisation de derives d'isoquinoline aux fins du traitement de cancers et d'etats pathologiques lies a la kinase associee aux membranes (map) - Google Patents
Utilisation de derives d'isoquinoline aux fins du traitement de cancers et d'etats pathologiques lies a la kinase associee aux membranes (map)Info
- Publication number
- MA27724A1 MA27724A1 MA28511A MA28511A MA27724A1 MA 27724 A1 MA27724 A1 MA 27724A1 MA 28511 A MA28511 A MA 28511A MA 28511 A MA28511 A MA 28511A MA 27724 A1 MA27724 A1 MA 27724A1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- cancer
- map
- related diseases
- membrane associated
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical class C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 title 1
- 239000012528 membrane Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 102000043136 MAP kinase family Human genes 0.000 abstract 1
- 108091054455 MAP kinase family Proteins 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000009929 raf Kinases Human genes 0.000 abstract 1
- 108010077182 raf Kinases Proteins 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45362403P | 2003-03-11 | 2003-03-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27724A1 true MA27724A1 (fr) | 2006-01-02 |
Family
ID=32990797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28511A MA27724A1 (fr) | 2003-03-11 | 2005-09-23 | Utilisation de derives d'isoquinoline aux fins du traitement de cancers et d'etats pathologiques lies a la kinase associee aux membranes (map) |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1603566B1 (https=) |
| JP (1) | JP2006519807A (https=) |
| KR (1) | KR20050108383A (https=) |
| CN (1) | CN1758910A (https=) |
| AT (1) | ATE421324T1 (https=) |
| AU (1) | AU2004218914A1 (https=) |
| BR (1) | BRPI0408257A (https=) |
| CA (1) | CA2518530A1 (https=) |
| DE (1) | DE602004019193D1 (https=) |
| ES (1) | ES2318276T3 (https=) |
| HR (1) | HRP20050788A2 (https=) |
| IS (1) | IS8064A (https=) |
| MA (1) | MA27724A1 (https=) |
| MX (1) | MXPA05009687A (https=) |
| NO (1) | NO20054647L (https=) |
| PL (1) | PL1603566T3 (https=) |
| PT (1) | PT1603566E (https=) |
| RU (1) | RU2325159C2 (https=) |
| TN (1) | TNSN05223A1 (https=) |
| TW (1) | TW200501955A (https=) |
| WO (1) | WO2004080464A1 (https=) |
| ZA (1) | ZA200506571B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05012377A (es) | 2003-05-15 | 2006-05-25 | Arqule Inc | Derivados de imidazotiazoles e imidazoxazol como inhibidores de p38. |
| AR045944A1 (es) * | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
| WO2006010082A1 (en) | 2004-07-08 | 2006-01-26 | Arqule, Inc. | 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase |
| JP2008517064A (ja) | 2004-10-19 | 2008-05-22 | アークル インコーポレイテッド | Ｐ３８ｍａｐキナーゼのイミダゾオキサゾールおよびイミダゾチアゾール阻害剤の合成 |
| CN101160131A (zh) * | 2005-02-25 | 2008-04-09 | 诺瓦提斯公司 | Bcr-abl和raf抑制剂的药物组合产品 |
| JP5049970B2 (ja) * | 2005-07-26 | 2012-10-17 | サノフイ | Ｒｈｏ−キナーゼ阻害剤としてのシクロヘキシルアミンイソキノロン誘導体 |
| US8318941B2 (en) | 2006-07-06 | 2012-11-27 | Bristol-Myers Squibb Company | Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| CA2639416C (en) * | 2007-09-11 | 2019-12-31 | F. Hoffmann-La Roche Ag | Diagnostic test for susceptibility to b-raf kinase inhibitors |
| EP3284494A1 (en) | 2009-07-30 | 2018-02-21 | Tandem Diabetes Care, Inc. | Portable infusion pump system |
| CN103038364A (zh) | 2010-03-09 | 2013-04-10 | 达纳－法伯癌症研究所公司 | 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法 |
| US9056855B2 (en) * | 2010-10-28 | 2015-06-16 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| CN103435430B (zh) * | 2013-08-08 | 2015-02-18 | 四川大学 | 一种还原酰胺类化合物的方法 |
| KR102119943B1 (ko) | 2018-05-23 | 2020-06-05 | 주식회사 포스코 | 시편배치유닛 및 이를 포함하는 도장밀착성 실험장치 |
| US20210275516A1 (en) * | 2018-07-02 | 2021-09-09 | Ecole Polytechnique Federale De Lausanne (Epfl) | Lactate enhancing compounds and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| ATE459616T1 (de) * | 1998-08-11 | 2010-03-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
| GT200000158A (es) * | 1999-09-28 | 2002-03-16 | Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis. | |
| PT1254138E (pt) * | 2000-02-09 | 2005-09-30 | Novartis Ag | Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf |
| US20030078271A1 (en) * | 2001-01-31 | 2003-04-24 | Blackburn Thomas P. | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
| DE60239097D1 (de) * | 2001-03-02 | 2011-03-17 | Gpc Biotech Ag | Drei-hybrid-assaysystem |
| MXPA04005561A (es) * | 2001-12-21 | 2004-12-06 | Bayer Pharmaceuticals Corp | Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina. |
| US7220775B2 (en) * | 2002-08-07 | 2007-05-22 | H. Lundbeck A/S | Compound useful for the treatment of neuropathic pain |
-
2004
- 2004-03-10 AT AT04718960T patent/ATE421324T1/de active
- 2004-03-10 RU RU2005131168/04A patent/RU2325159C2/ru not_active IP Right Cessation
- 2004-03-10 BR BRPI0408257-5A patent/BRPI0408257A/pt not_active IP Right Cessation
- 2004-03-10 CA CA002518530A patent/CA2518530A1/en not_active Abandoned
- 2004-03-10 AU AU2004218914A patent/AU2004218914A1/en not_active Abandoned
- 2004-03-10 DE DE602004019193T patent/DE602004019193D1/de not_active Expired - Lifetime
- 2004-03-10 PT PT04718960T patent/PT1603566E/pt unknown
- 2004-03-10 JP JP2006504625A patent/JP2006519807A/ja active Pending
- 2004-03-10 EP EP04718960A patent/EP1603566B1/en not_active Expired - Lifetime
- 2004-03-10 MX MXPA05009687A patent/MXPA05009687A/es active IP Right Grant
- 2004-03-10 TW TW093106341A patent/TW200501955A/zh unknown
- 2004-03-10 CN CNA2004800065706A patent/CN1758910A/zh active Pending
- 2004-03-10 HR HR20050788A patent/HRP20050788A2/xx not_active Application Discontinuation
- 2004-03-10 WO PCT/EP2004/002460 patent/WO2004080464A1/en not_active Ceased
- 2004-03-10 KR KR1020057016936A patent/KR20050108383A/ko not_active Ceased
- 2004-03-10 PL PL04718960T patent/PL1603566T3/pl unknown
- 2004-03-10 ES ES04718960T patent/ES2318276T3/es not_active Expired - Lifetime
-
2005
- 2005-08-17 ZA ZA200506571A patent/ZA200506571B/en unknown
- 2005-09-09 TN TNP2005000223A patent/TNSN05223A1/en unknown
- 2005-09-23 MA MA28511A patent/MA27724A1/fr unknown
- 2005-10-10 IS IS8064A patent/IS8064A/is unknown
- 2005-10-10 NO NO20054647A patent/NO20054647L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006519807A (ja) | 2006-08-31 |
| CN1758910A (zh) | 2006-04-12 |
| NO20054647D0 (no) | 2005-10-10 |
| PT1603566E (pt) | 2009-04-27 |
| MXPA05009687A (es) | 2005-10-20 |
| WO2004080464A1 (en) | 2004-09-23 |
| EP1603566B1 (en) | 2009-01-21 |
| AU2004218914A1 (en) | 2004-09-23 |
| TNSN05223A1 (en) | 2007-06-11 |
| DE602004019193D1 (de) | 2009-03-12 |
| ATE421324T1 (de) | 2009-02-15 |
| HRP20050788A2 (en) | 2006-12-31 |
| RU2325159C2 (ru) | 2008-05-27 |
| IS8064A (is) | 2005-10-10 |
| CA2518530A1 (en) | 2004-09-23 |
| PL1603566T3 (pl) | 2009-07-31 |
| TW200501955A (en) | 2005-01-16 |
| ZA200506571B (en) | 2006-07-26 |
| ES2318276T3 (es) | 2009-05-01 |
| NO20054647L (no) | 2005-12-09 |
| BRPI0408257A (pt) | 2006-03-07 |
| RU2005131168A (ru) | 2006-05-27 |
| EP1603566A1 (en) | 2005-12-14 |
| KR20050108383A (ko) | 2005-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA27724A1 (fr) | Utilisation de derives d'isoquinoline aux fins du traitement de cancers et d'etats pathologiques lies a la kinase associee aux membranes (map) | |
| TNSN06093A1 (en) | 1,4- disubstituted isoquinoline derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | |
| ATE402929T1 (de) | Pyrazinverbindungen als inhibitoren des transforming growth factor (tgf) | |
| TNSN05045A1 (en) | Indole or benzimidazole derivatives for modulating ikappab kinase | |
| EA200700321A1 (ru) | Пиразолзамещённые аминогетероарильные соединения в качестве ингибиторов протеинкиназы | |
| ATE401076T1 (de) | Chinolinderivate als glucokinase liganden | |
| NO2013008I2 (no) | Krizotinib eller et farmasøytisk akseptabelt salt, hydrat eller solvat derav | |
| MXPA05009595A (es) | Compuestos 7-amino-isoindolilo y sus usos farmaceuticos. | |
| DE69430747D1 (de) | Verbindungen als pde iv und tnf inhibitoren | |
| NO20026242L (no) | Syntesemetoder for aplidin og nye antitumorale derivater, metoder for deresfremstilling og anvendelse av disse | |
| GB0112348D0 (en) | Compounds | |
| PT1390371E (pt) | Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores | |
| CO5660287A2 (es) | Derivados de tetrahidrocarbazol y su uso farmaceutico | |
| ATE329909T1 (de) | 1,2,3-triazolamid-derivate als cytokininhibitoren | |
| ATE367380T1 (de) | Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate | |
| DE60325377D1 (de) | Motilidverbindungen | |
| IL166057A0 (en) | Urea-substituted and urethane-substituted acylureas methods for the production thereof and their useas medicaments | |
| EA200600992A1 (ru) | Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение | |
| DE60131968D1 (de) | PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN | |
| DE60318320D1 (de) | Benzimidazolone und ihre verwendung als cytokininhibitoren | |
| CY1106576T1 (el) | Υποκατεστημενα παραγωγα 2-πυρρολιδιν-2-υλ-1h-ινδολης για τη θεραπεια ημικρανιας | |
| ATE445611T1 (de) | Regiospezifische synthese von nikotinderivaten | |
| ATE423780T1 (de) | Makrozyclen zur behandlung von krebserkrankungen | |
| DE60120398D1 (de) | Imidazopyridin-8-one | |
| ATE503476T1 (de) | Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind |